Medical Hypotheses
Volume 59, Issue 3 , Pages 297-301 , September 2002

Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure

  • Doron Aronson

      Affiliations

    • Corresponding Author InformationCorrespondence to: Doron Aronson MD, Department of Cardiology, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel. Phone: +972-48-542790; Fax: +972-48-542176

Received 20 December 2001 ,Accepted 4 April 2002.

References 

  1. Bittl JA. Advances in coronary angioplasty. N. Engl. J. Med. 1996;335:1290–1302
  2. Elezi S, Kastrati A, Pache J, et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J. Am. Coll. Cardiol. 1998;32:1866–1873
  3. Azar RR, Prpic R, Ho KK, et al.  Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am. J. Cardiol. 2000;86:485–489
  4. Koyanagi T, Nishida H, Kitamura M, et al.  Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann. Thorac. Surg. 1996;61:1793–1796
  5. Marso SP, Gimple LW, Philbrick JT, DiMarco JP. Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis. Am. J. Cardiol. 1998;82:378–380
  6. Carrozza JP, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann. Intern. Med. 1993;118:344–349
  7. Moreno PR, Bernardi VH, Lopez Cuellar J, et al.  Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation. 1996;94:3098–3102
  8. Van Belle E, Ketelers R, Banters C, et al.  Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103:1218–1224
  9. The Bypass Angioplasty Revascularization Investigation (BARI) investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–225
  10. O'Neill WW. Multivessel balloon angioplasty should be abandoned in diabetic patients!. J. Am. Coll. Cardiol. 1998;31:20–22
  11. Kornowski R, Mintz GS, Kent KM, et al.  Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997;95:1366–1369
  12. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am. J. Cardiol. 2000;86:6H–11H
  13. Hoffmann R, Mintz GS, Dussaillant GR, et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247–1254
  14. Farb A, Sangiorgi G, Carter AJ, et al.  Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44–52
  15. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224–233
  16. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neomtimal hyperplasia. J. Am. Coll. Cardiol. 1998;31:224–230
  17. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neomtimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 1996;16:1312–1318
  18. Libby P, Ganz P. Restenosis revisited—new targets, new therapies. N. Engl. J. Med. 1997;337:418–419 [editorial; comment]
  19. Tardif JC, Cote G, Lesperance J, et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasry. Multivitamins and Probucol Study Group. N. Engl. J. Med. 1997;337:365–372 [see comments]
  20. Schwartz R, Holmes D, Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 1992;20:1284–1293
  21. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988;318:1315–1321
  22. Park L, Raman KG, Lee KJ, et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998;4:1025–1031
  23. Makita Z, Radoff S, Rayfield EJ, et al.  Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 1991;325:836–842 [see comments]
  24. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int. 1999;55:389–399
  25. Niwa T, Katsuzaki T, Miyazaki S, et al.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J. Clin. Invest. 1997;99:1272–1280
  26. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int. 1997;52:1064–1067
  27. Makita Z, Bucala R, Rayfield EJ, et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519–1522
  28. Soulis T, Thallas V, Youssef S, et al.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia. 1997;40:619–628
  29. Palinski W, Koschinsky T, Butler SW, et al.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler. Thromb. Vasc. Biol. 1995;15:571–582
  30. Brett J, Schmidt AM, Yan SD, et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 1993;143:1699–1712
  31. Nishikawa T, Edelstein D, Du XL, et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790
  32. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J. Clin. Invest. 1996;97:1422–1428
  33. Ritthaler U, Deng Y, Zhang Y, et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am. J. Pathol. 1995;146:688–694
  34. Schmidt AM, Hori O, Cao R, et al.  RAGE: a novel cellular receptor for advanced glycation end products. Diabetes. 1996;45(suppl. 3):S77–S80
  35. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000;275:25781–25790
  36. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface- binding proteins for advanced glycation end products. J. Clin. Invest. 1993;91:2155–2168
  37. Vlassara H. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes. 1992;41(suppl. 2):52–56
  38. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA. 1990;87:9010–9014
  39. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 1992;90:439–446
  40. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and 1L-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988;240:1546–1548
  41. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic-vasculopathy and atherosclerosis. Circ. Res. 1999;84:489–497
  42. Higashi T, Sano H, Saishoji T, et al.  The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes. 1997;46:463–472
  43. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997;272:17810–17814
  44. Indolfi C, Avvedimento EV, Rapacciuolo A, et al.  Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat. Med. 1995;1:541–545 [see comments]
  45. Pyles JM, March KL, Franklin M, Mehdi K, Wilensky RL, Adam LP. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries. Circ. Res. 1997;81:904–910
  46. Wautier JL, Zoukourian C, Chappey O, et al.  Receptor-mediated endothelial cell dysfunction in diabetic vasculopalhy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 1996;97:238–243
  47. Yan SD, Schmidt AM, Anderson GM, et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994;269:9889–9897
  48. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J. Clin. Invest. 1994;93:1172–1178
  49. Rumble JR, Cooper ME, Soulis T, et al.  Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J. Clin. Invest. 1997;99:1016–1027
  50. Pugliese G, Pricci F, Romeo G, et al.  Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes. 1997;46:1881–1887
  51. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629–1632

PII: S0306-9877(02)00172-X

Medical Hypotheses
Volume 59, Issue 3 , Pages 297-301 , September 2002

Article Tools

* Image Usage & Resolution